点击蓝字关注我们编者按：作为全球肿瘤学领域的顶级盛会，2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林盛大举办。届时，来自世界各地的临床医生、研究人员、患者倡导者、记者和医疗行业专业人士将齐聚一堂，展示开创性的发现、前沿治疗方法，并倡导协作方式，推动肿瘤治疗的未来发展。日前，大会公布了本次入选摘要的标题，其中在血液肿瘤领域共有28项中国研究入选（如遗漏欢迎留言补充），展示了中国在该领域的最新突破与创新成果。以下是入选摘要及相关汇报者的信息，敬请关注。特邀论文报告Proffered Paper session摘要号：1240O英文题目：CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial中文题目：CD19/CD22双特异性CAR-T细胞治疗复发/难治性大B细胞淋巴瘤：一项前瞻性、单臂、单中心、II期临床试验汇报者：王亮（首都医科大学附属北京同仁医院）摘要号：1241O英文题目：Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial中文题目：抗PD-1抗体（替雷利珠单抗）联合西达本胺、来那度胺和依托泊苷治疗难治性/复发性鼻型结外自然杀伤/T细胞淋巴瘤：一项前瞻性、多中心、单臂、II期试验的初步结果汇报者：张蕾（郑州大学第一附属医院）小型口头报告Mini Oral session摘要号：1243MO英文题目：Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study中文题目：整合中期18F-FDG PET-CT分析和NCCN-IPI对弥漫性大B细胞淋巴瘤进行风险分层：一项多中心回顾性研究汇报者：王杰松（福建省肿瘤医院）摘要号：1245MO英文题目：Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study中文题目：盐酸米托蒽醌脂质体联合西达本胺治疗复发或难治性外周T细胞淋巴瘤：II期研究更新结果汇报者：李志铭（中山大学肿瘤防治中心）摘要号：1246MO英文题目：Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies中文题目：单细胞循环免疫图谱揭示了可预测对R-CHOP和抗CD19 CAR-T疗法应答的共同特异性DLBCL特征汇报者：张思聪（天津医科大学肿瘤医院）摘要号：1247MO英文题目：Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses中文题目：不同滤泡性淋巴瘤组织学分级的分子图谱：来自基因组和转录组分析的见解汇报者：孙聪（天津医科大学肿瘤医院）摘要号：1248MO英文题目：Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia中文题目：急性髓系白血病含维奈克拉方案治疗前后外周血白血病干细胞、免疫细胞亚群、细胞因子及细胞分化状态的变化汇报者：Xinyu Sun（中国合肥）壁报与电子壁报Posters and ePosters摘要号：1251P 英文题目：DLBCL-associated PIM1 mutation drives ANXA2 relocation on the membrane and promotes lymphomagenesis through PI3K/AKT/mTOR pathway中文题目：DLBCL相关的PIM1突变驱动ANXA2移位至膜上并通过PI3K/AKT/mTOR通路促进淋巴瘤发生汇报者：Yaxiao Lu (中国天津)摘要号：1254P英文题目：Clinical features, management, and prognostic factors of patients with primary pulmonary mucosa-associated lymphoid tissue lymphoma中文题目：原发性肺黏膜相关淋巴组织淋巴瘤患者的临床特征、管理及预后因素汇报者：Yizhen Liu (中国上海)摘要号：1256P英文题目：Integrating Transcriptomic Profiling and Machine Learning: A Clinically Actionable Prognostic Model for Infant Acute Myeloid Leukemia中文题目：整合转录组学分析与机器学习：婴儿急性髓性白血病的临床可操作预后模型汇报者：Yu Tao (中国重庆)摘要号：1257P英文题目：Phase I Randomized, Double-Blind, Parallel Study to Compare Pharmacokinetics, Safety, and Immunogenicity of QL2109 with DARZALEX FASPRO? in Healthy Male Participants中文题目：比较QL2109与DARZALEX FASPRO在健康男性参与者中的药代动力学、安全性和免疫原性的I期随机、双盲、平行研究汇报者：Xingjiang Hu (中国杭州)摘要号：1262P英文题目：A Deep Learning-Based Digital Pathology Model for Predicting MYC, BCL2, and BCL6 Rearrangements in DLBCL中文题目：基于深度学习的数字病理模型用于预测DLBCL中MYC、BCL2和BCL6的重排汇报者：Xujie Sun (中国北京)摘要号：1264P英文题目：Orelabrutinib plus Rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: a multicentric phase II trial中文题目：奥布替尼联合利妥昔单抗治疗复发或难治性边缘区淋巴瘤的化学免疫治疗方案：一项多中心II期临床试验汇报者：Shaohua Wu (中国太原)摘要号：1265P英文题目：Orelabrutinib with Anti-CD20 monoclonal antibodies is highly effective and well tolerated as first-line therapy for marginal zone B cell lymphoma中文题目：奥布替尼联合抗CD20单克隆抗体一线治疗边缘区B细胞淋巴瘤的疗效显著且耐受性良好汇报者：Na Yao (中国北京)摘要号：1266P英文题目：Proteolysis-targeting chimera (PROTAC) targeting BTK degradation for cancer therapy in mantle cell lymphoma中文题目：靶向BTK降解的蛋白降解靶向嵌合体（PROTAC）在套细胞淋巴瘤癌症治疗中的应用汇报者：Xiaohui Wang (中国天津)摘要号：1269P英文题目：Loss of MGAT3 promotes airway fibrosis in patients with bronchiolitis obliterans by enhancing TGF-β signaling中文题目：MGAT3缺失通过增强TGF-β信号通路促进支气管炎性小气道纤维化汇报者：Wei Ge (中国苏州)摘要号：1270P英文题目：Safety and efficacy of a pre-phase with dexamethasone followed by fractioned R-CHOP in diffuse large B cell lymphoma patients with gastrointestinal involvement at diagnosis中文题目：地塞米松预处理联合R-CHOP分次治疗对确诊时有胃肠道损害的弥漫大B细胞淋巴瘤患者的安全性和有效性汇报者：Ke Cui (中国上海)摘要号：1274P英文题目：A transcriptomic model accurately predicting hematopoietic stem cell transplantation survival in pediatric acute myeloid leukemia中文题目：准确预测儿童急性髓系白血病造血干细胞移植存活率的转录组模型汇报者：Yance Feng (中国重庆)摘要号：1275P英文题目：Efficacy and Safety of Low-Dose TBI Combined MAC Regimen for HSCT in High-Risk AML Patients with Active Disease中文题目：低剂量TBI联合MAC方案对活动期高危AML患者造血干细胞移植的疗效及安全性汇报者：Pengfei Shi (中国杭州)摘要号：1276P 英文题目：Efficacy and Safety of Tafasitamab Combined with Lenalidomide in Patients with Diffuse Large B-Cell Lymphoma: A Matched-Adjusted Indirect Comparison Based on a Global Trial中文题目：Tafasitamab联合来那度胺治疗弥漫大B细胞淋巴瘤的疗效和安全性：基于全球试验的匹配调整间接比较汇报者：Wenyu Li (中国广州)摘要号：1279P英文题目：Risk Stratification and Therapeutic Suggestions for High-risk RUNX1::RUNX1T1-positive pAML patients中文题目：高危 RUNX1::RUNX1T1 阳性pAML患者的风险分层和治疗建议汇报者：Yang Xun (中国佛山)摘要号：1281P英文题目：Targeting miR-20a/RUNX1 exerts the dual functions of blocking CD8+ T cell exhaustion and anti-leukemia effect in acute myeloid leukemia中文题目：靶向 miR-20a/RUNX1在急性髓系白血病中发挥阻断CD8+ T细胞耗竭和抗白血病作用的双重作用汇报者：Yangqiu Li (中国广州)摘要号：1285P英文题目：HIF-2α expression predicts inferior survival and can broaden the poor clinical outcome of patients with Foxp3- and NF-κB+ in DLBCL中文题目：HIF-2α表达预示较差的生存期，并可加剧伴有Foxp3和NF-κB+的DLBCL患者的临床不良结局汇报者：Yaoyao Jing (中国天津)摘要号：1291eP英文题目：Pola-R-CHP Regimen as First-Line Treatment for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients中文题目：Pola-R-CHP方案作为新诊断高危弥漫大B细胞淋巴瘤 (DLBCL)患者的一线治疗汇报者：Jinping Pi (中国北京)摘要号：1294eP英文题目：Efficacy of Orelabrutinib Combined with R-CHOP(-like) Regimen in Previously Untreated Double-expression (DE) Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis中文题目：奥布替尼联合R-CHOP(类)方案治疗既往未治疗的双表达(DE)弥漫大B细胞淋巴瘤(DLBCL)的疗效：单中心真实世界分析汇报者：Min Bai (中国太原)摘要号：1298eP英文题目：PD-1/CD20 Dual-Target Therapy in Unfit Diffuse Large B-Cell Lymphoma: A Real-World Pilot Study中文题目：PD-1/CD20双靶点疗法治疗Unfit弥漫大B细胞淋巴瘤：一项真实世界先导研究汇报者：Shaozhen Chen (中国福州)摘要号：1299eP 英文题目：ADGRE2: a tumor-restricted surface antigen for immunotherapy in acute myeloid leukemia中文题目：ADGRE2：急性髓性白血病免疫治疗的肿瘤特异性表面抗原汇报者：Ruotong Chen(中国合肥)摘要号：1300eP英文题目：Synergistic Effect of Vincristine and Cytarabine via Targeting the ALDOC-JAK/STAT Axis for NRASmut Acute Myeloid Leukemia中文题目：长春新碱与阿糖胞苷通过靶向ALDOC-JAK/STAT轴对NRASmut急性髓系白血病的协同效应汇报者：Haotian Yan(中国合肥)（来源：《肿瘤瞭望–血液时讯》编辑部）声 明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
